Loading...
Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
INTRODUCTION: In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day. It is usually assumed that the increased h...
Na minha lista:
| Udgivet i: | Diabetes Ther |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Healthcare
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4269641/ https://ncbi.nlm.nih.gov/pubmed/25230877 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-014-0082-y |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|